Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. - Wikidata - wikimedia - TriplyDB

Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

http://www.wikidata.org/entity/Q36819564

about

Crohn's disease in women New approaches for managing preeclampsia: clues from clinical and basic research An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation?A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study.Pregnancy and autoimmune connective tissue diseases Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education From conception to delivery: managing the pregnant inflammatory bowel disease patient.Inflammatory bowel disease and preterm delivery.Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure.Targeting TNF-α for the treatment of inflammatory bowel disease.Management of gastrointestinal and liver diseases during pregnancy.Certolizumab pegol for the treatment of psoriatic arthritis.Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use.Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy.A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation.Pyoderma gangrenosum during pregnancy - treatment options revisited.Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.Maternal obesity and inflammatory mediators: A controversial association.Intra-uterine experimental infection by Ureaplasma diversum induces TNF-α mediated womb inflammation in mice.Psoriasis in pregnancy: challenges and solutions.

P2860

Q26851451-A29D25C8-AF4B-442B-9293-80DD46B29FF2 Q27010670-D100AAE5-9A26-49D8-B8FA-500F667E54A7 Q28074393-0B7C47E1-950D-49A2-8DFD-119987E2B7BE Q34389362-20A3C659-59B8-480C-87B3-ACD67113316D Q35915182-6D7F472D-1721-480D-9C6F-E4ECD5697D05 Q35973766-BA350E4D-570D-4044-B050-95634289DA8A Q36125487-C3BB1A81-D289-484C-9EA2-941E9B11000A Q37100267-0E16ACC2-83C7-4175-B18D-65BA7C6CA233 Q37306723-4CEC87B5-36AA-4BBB-A0F4-2DEC9B1700D2 Q37682503-010C9548-9101-4E87-ACB4-C5883099C986 Q38128204-CCF759F6-0315-4175-AFB7-029E6617757B Q38160896-C7EBD4BF-AC17-4447-AA45-1DD6A62B8AC0 Q38160905-23911443-7A48-4E6D-B4DD-1CE0DAD1C316 Q38178818-3BC66E31-201B-4712-B96F-52A72842E407 Q38344194-0168D3FD-6661-4D6A-ACD1-9DD393D786BC Q38652430-3CF087A7-AE4A-4048-A8D4-36F69FDF954F Q38661263-3E270905-3F35-4B8F-87CC-86DF3CF09DDF Q38707864-D886CB02-BB65-41E1-980A-E59B14D5417A Q38820088-70DE3576-F50F-4F17-90F8-ACB3E76B9FC6 Q38880894-D82E073C-BA03-4E5A-9B6B-C2273EA58BC8 Q39029592-19D879EB-A4F5-465D-9B0F-2DDB4DC3D450 Q39192889-12D6425B-03EB-47F4-8C24-69D970C8FD63 Q40793762-64EF6C88-25B1-4251-971D-A0EC6DFB4751 Q55553649-55AEE96E-5E3A-4AE4-86DB-D8ED763C2C25

P2860

Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

http://www.wikidata.org/entity/Q36819564

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

@ast

Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

@en

type

label

Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

@ast

Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

@en

prefLabel

Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

@ast

Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

@en

P1433

Q36819564-D64CB02B-3404-4FAF-8DF0-3D9D67CBFF96

P1476

Q36819564-2D2B0083-4844-4C89-AE13-559D2F640898

P2093

Q36819564-457F66A7-9408-4DF7-8A4F-C059632E2DDA

Q36819564-FD54FBA0-C132-4311-B438-82E0E492E9E0

P2860

Q36819564-055A9CA4-4228-40FD-A583-251C79D24E05

Q36819564-0729C3F1-48C7-4522-A745-1CDB3E2158E2

Q36819564-0D9EC34B-BE60-4CAE-8ADD-64113AF2ED4C

Q36819564-1B1DFBCD-4C9E-40CD-9E66-21BD9DDAF955

Q36819564-27F698C2-D037-4EC3-9364-42B2C41652BD

Q36819564-332322D1-8EAB-4F35-9E50-C4845018E0EB

Q36819564-3422CAE9-480D-4CAE-AD9C-1C4D0DA8950D

Q36819564-37C54633-6F38-4AA7-8790-6988A95DB491

Q36819564-3DD1CB42-B35B-41D0-A04E-0C1EF8790C03

Q36819564-3EDDDEBE-1305-4FE8-B206-2FE274AB48B2

P304

Q36819564-0A6D1EF8-F787-4C5D-B479-5592350FC488

P31

Q36819564-4A3A889D-2C92-432E-A5E5-9DF19F1F16B4

P356

Q36819564-2335151B-0412-41ED-8B66-B961BD238450

P407

Q36819564-363926AB-F85A-45E3-8C26-DE929FA6B18F

P433

Q36819564-BDE91B7A-5D7A-49DF-9ECB-F637054257CB

P478

Q36819564-215ACFA3-DB4F-449E-887B-D3DB825261E9

P577

Q36819564-71D105B0-7B22-4170-9A0D-F5A07C0624CB

P5875

Q36819564-494E1A7D-6DD1-4CCB-9CC8-708DBF583EF0

P698

Q36819564-B9B224B7-9CEA-4D52-8BE3-7BAEBC5FB807

P932

Q36819564-A3DE389A-C8C2-4B80-B04F-07B9892CC3E6

P356

WJG.V19.I17.2591

P1433

World Journal of Gastroenterology

P1476

Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

@en

P2093

Gary R Lichtenstein

http://www.w3.org/2001/XMLSchema#string

Renée M Marchioni

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

Epidemiology and the natural course of inflammatory bowel disease.

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Births: final data for 2008.

Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease.

Inflammatory bowel disease in pregnancy.

American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy.

Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy.

P304

2591-2602

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V19.I17.2591

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236837920

http://www.w3.org/2001/XMLSchema#string

P698

23674866

http://www.w3.org/2001/XMLSchema#string

P932

3645377

http://www.w3.org/2001/XMLSchema#string